Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Transdermal Method and Patch for Nausea

a technology of transdermal devices and patches, applied in the field of transdermal devices and methods for the treatment can solve the problems of nausea and vomiting, difficulty in antiemetic agents, and side effects of treatmen

Inactive Publication Date: 2006-11-23
ABEILLE PHARMA
View PDF13 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007] Attempts to develop a transdermally administered antiemetic agent have raised other problems. For example, some penetration enhancers used in transdermal compositions, (e.g., terpenes), induce skin irritation. Alcohols, which are often needed to solubilize the antiemetic agent for transdermal applications, are also irritating to the skin. Also, because of rapid depletion of the alcohol, sustained delivery over a period greater than a few hours is difficult to achieve. When a transdermal composition consisting of a solution with a low viscosity is used, the blood level of the drug may easily drop below the effective level thus lessening the desired pharmacological effect.
[0009] Thus, it is desirable to provide a transdermal composition of an antiemetic agent which is simple to use, nonirritating to the skin and which may be left in place on the skin for 24 hours, two days, three days or more for continuously and effectively preventing, ameliorating or treating nausea and vomiting. Moreover, with modest but functionally significant concentrations of active and permeation enhancer, it is nonetheless possible using the current teachings to formulate a patch that delivers antiemetic agent over a very substantial time period, and even maintain delivery as measured at the blood level well after removal of the composition.

Problems solved by technology

Most patients undergoing anticancer treatment either by chemotherapy or radiation suffer from side effects of the treatment such as nausea and vomiting, a common complaint by patients.
In any situation where a patient is suffering from nausea and vomiting, oral administration of an antiemetic agent is challenging and creates more discomfort for the patient.
Intravenous (IV) or intramuscular (IM) administration is generally impractical for home use.
Additionally, since nausea and vomiting are challenging to reverse, antiemetic agents are most effective if given prophylactically.
Attempts to develop a transdermally administered antiemetic agent have raised other problems.
For example, some penetration enhancers used in transdermal compositions, (e.g., terpenes), induce skin irritation.
Alcohols, which are often needed to solubilize the antiemetic agent for transdermal applications, are also irritating to the skin.
Also, because of rapid depletion of the alcohol, sustained delivery over a period greater than a few hours is difficult to achieve.
When a transdermal composition consisting of a solution with a low viscosity is used, the blood level of the drug may easily drop below the effective level thus lessening the desired pharmacological effect.
Other efforts to administer antiemetic agents transdermally have included complicated application devices or techniques such as supplemental energy to enhance the transdermal penetration of the drug.
However, salt forms of antiemetic agents have relatively low transdermal permeabilities, and it is difficult to achieve therapeutic plasma levels over a sustained period.
Use of the free base form is typically not considered since it could be irritating or considered to be unstable in the dosage form.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Transdermal Method and Patch for Nausea
  • Transdermal Method and Patch for Nausea
  • Transdermal Method and Patch for Nausea

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Adhesive Mixture and Transdermal Delivery Device

[0071]

TABLE 1CompositionFormulation AFormulation BPatch Size15.0 cm215.0 cm2Estimated Target Daily1.2 mg1.2 mgDoseDry %Dry %Styrene-butadiene rubber44.04—pressure sensitive adhesiveAcrylate-vinylacetate—43.8pressure sensitive adhesiveIsopropyl Myristate3.014.07Granisetron Base3.053.05Polyester Release liner35.835.8Polyester Backing13.313.3

Components

[0072] Formulation A and Formulation B were prepared using the amounts of each component as shown in Table 1 above.

[0073] The styrene-butadiene rubber pressure sensitive adhesive used in the examples herein was DURO-TAK®87-6173 adhesive, available from National Starch and Chemical in Bridgewater, N.J. The acrylate-vinylacetate pressure sensitive adhesive used in the examples herein was DURO-TAK®87-2516 adhesive, available from National Starch and Chemical in Bridgewater, N.J. The isopropyl myristate used in the examples herein was of NF grade. The polyester release liner u...

example 2

Test for Flux of Granisetron from the Transdermal Delivery Device

Procedure

[0077] Heat-separated human cadaver skin was cut to the desired size and mounted on a Franz diffusion cell. The release liner was peeled away from a patch made according to Formulation B as described in EXAMPLE 1 above. The patch was placed on the skin and the patch and skin were clamped together. Receptor solution was added to the diffusion cell, and the assembly was maintained at 32° C. Aliquots of the receptor solution were taken at periodic time points (24 hours, 48 hours, 72 hours, 96 hours, and 120 hours). The concentration of the granisetron in the receptor solution was measured at each time point, and the flux rate from examples A and B was calculated. The resulting data is illustrated in FIG. 1. Cumulative delivery of granisetron over the indicated time was likewise calculated from the concentration of granisetron in the receptor solution at each time point and is illustrated in FIG. 2.

example 3

Stability of Granisetron in Illustrative Examples

[0078]

TABLE 2Formulation CFormulation DCompositionDry %Dry %Styrene-butadiene rubber49.88% —pressure sensitive adhesiveAcrylate-vinylacetate43.77% pressure sensitive adhesiveIsopropyl Myristate—5.09%Granisetron Base*1.02%2.04%Polyester Release liner35.8%35.8%Polyester Backing13.3%13.3%

[0079] Patches were made according to the procedure described in Example 1 above using the formulations shown in Table 2. The patches were then tested for granisetron stability using the method described below.

[0080] Samples of the patches are stored at 50° C. for up to 2 months. Stability of the product is assessed by testing periodically for granisetron content and the total amount of impurities using high performance liquid chromatography. The results are shown below in Table 3.

TABLE 3Total impuritiesGranisetron Potency(% of granisetron)(% w / w)Formu-TimeFormulation CFormulation Dlation CFormulation DTo99.999.50.050.251 month at99.899.20.120.4150° ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
areaaaaaaaaaaa
timeaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

Provided, among other things, is a method of treating acute, delayed or anticipatory emesis for a sustained period in an individual, which involves applying to a portion of intact skin on the individual a composition of i. an antiemetically effective amount of a 5-HT3 receptor antagonist; ii. a permeation enhancing amount of permeation enhancer comprising 0.5% to 15% by weight of the skin-contacting layer; and iii. an adhesive, wherein a plasma concentration of the 5-HT3 receptor antagonist in a therapeutically effective range is provided for period of time from an onset time to 12 hours or more after the composition is removed.

Description

[0001] This application claims the priority of U.S. Application 60 / 682,251, filed May 18, 2005, U.S. Application 60 / 702,744, filed Jul. 27, 2005, and U.S. Application 60 / 759,381, filed Jan. 17, 2006.[0002] The present invention relates to a transdermal device and method for the treatment of nausea and vomiting, and more particularly to a transdermal method, composition, and device containing a 5-HT3 receptor antagonist for the treatment of nausea and vomiting for a sustained period of time. [0003] Most patients undergoing anticancer treatment either by chemotherapy or radiation suffer from side effects of the treatment such as nausea and vomiting, a common complaint by patients. To prevent or minimize these side effects of anticancer treatments, antagonists of 5-hydroxytryptamine subtype 3 (hereinafter referred to as ‘serotonin’) such as ondansetron, granisetron, tropisetron, dolasetron, hydrodolasetron, azasetron, ramosetron, lerisetron, indisetron, itasetron, palonosetron, lamoset...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/573A61K31/41A61L15/16A61F13/02
CPCA61K9/7061A61K9/7053A61P1/06A61P1/08A61P43/00C07G15/00
Inventor PATEL, KALPANA J.BORSADIA, SURESH
Owner ABEILLE PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products